In patients with type 2 diabetes mellitus, the advantages of sodium glucose cotransporters 2 (SGLT2) inhibitors include plasma glucose regulation, a decrease in body weight and blood pressure, and a low risk of hypoglycemia. Dapagliflozin, an inhibitor of SGLT2, promotes patient satisfaction by reducing HbA1c (glycated hemoglobin) and body weight. 1 To throw more light on the same, Dr. Reddy's and Docplexus have organized an interactive webinar on 21 st January 2021 at 04:30 PM . In this session, Dr.
Shashank Joshi and Prof. (Dr). Upendra Kaul shall discuss “ Improved Outcomes With DAPAGLIFLOZIN .” Agenda: We invite you to share your questions, which will be answered by the speakers at the end of the session. Reference: Nakajima H, Okada S, Mohri T, Kanda E, Inaba N, Hirasawa Y, Seino H, Kuroda H, Hiyoshi T, Niiya T, Ishii H. Dapagliflozin improves treatment satisfaction in…
